
Medicine
Cancer treatment, made to measure.
A personalized melanoma vaccine reports a promising result in a large trial.
Read the story +
A treatment designed around a person’s tumor has cleared an important research test. Merck and Moderna report that adding the investigational vaccine intismeran to pembrolizumab improved recurrence-free survival after surgery for high-risk melanoma.
The randomized phase 3 trial enrolled 1,137 patients. At two years, estimated recurrence-free survival was 82.2% with the combination and 70.0% with pembrolizumab alone. Those figures concern recurrence or death during follow-up; they are not cure rates.
Treatment caused side effects, and overall-survival results are still immature. The vaccine remains investigational. This is a therapeutic approach for people already diagnosed with melanoma, rather than a preventive vaccine for healthy people.
The encouraging idea is precise: help the immune system recognize features of the particular cancer it needs to fight.
Merck and Moderna: phase 3 results ↗Source published October 22, 2026


